Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

Anne Sophie Kubasch; Freya Schulze; Aristoteles Giagounidis; Katharina S Götze; Jan Krönke; Katja Sockel; Jan Moritz Middeke; Fatiha Chermat; Silke Gloaguen; Martin Puttrich; Carmen Weigt; Doreen William; Pierre Fenaux; Richard F Schlenk; Christian Thiede; Sebastian Stasik; Anna Mies; Lionel Adès; Uta Oelschlägel; Uwe Platzbecker

doi:10.1038/s41375-019-0645-z

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

Leukemia. 2020 Apr;34(4):1182-1186. doi: 10.1038/s41375-019-0645-z. Epub 2019 Dec 3.

Authors

Anne Sophie Kubasch^#^{1

2

3}, Freya Schulze^#^{2

3

4}, Aristoteles Giagounidis^{2

3

5}, Katharina S Götze^{2

3

6}, Jan Krönke^{2

3

7}, Katja Sockel^{2

3

4}, Jan Moritz Middeke^{2

3

4}, Fatiha Chermat^{3

8}, Silke Gloaguen^{2

3}, Martin Puttrich^{3

9}, Carmen Weigt^{3

9}, Doreen William^{10

11}, Pierre Fenaux^{3

8

12}, Richard F Schlenk^{3

11

13}, Christian Thiede^{3

4}, Sebastian Stasik^{3

4}, Anna Mies^{3

4}, Lionel Adès^{3

8

12}, Uta Oelschlägel^{2

3

4}, Uwe Platzbecker^{14

15

16}

Affiliations

¹ Medical Clinic and Policlinic I, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany.
² German MDS Study Group (D-MDS), Leipzig, Germany.
³ The European Myelodysplastic Syndromes Cooperative Group (EMSCO), Leipzig, Germany.
⁴ Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.
⁵ Department for Oncology, Hematology and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany.
⁶ Department of Medicine III, Klinikum rechts der Isar, TUM, Munich, Germany.
⁷ Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
⁸ Groupe Francophone des Myélodysplasies, Paris, France.
⁹ GWT-TUD GmbH, Dresden, Germany.
¹⁰ Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.
¹¹ National Center for Tumor Diseases (NCT), Heidelberg, Germany.
¹² Service d'Hématologie Seniors, Assistance Publique-Hôpitaux de Paris and Paris University, Paris, France.
¹³ Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
¹⁴ Medical Clinic and Policlinic I, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany. uwe.platzbecker@medizin.uni-leipzig.de.
¹⁵ German MDS Study Group (D-MDS), Leipzig, Germany. uwe.platzbecker@medizin.uni-leipzig.de.
¹⁶ The European Myelodysplastic Syndromes Cooperative Group (EMSCO), Leipzig, Germany. uwe.platzbecker@medizin.uni-leipzig.de.

^# Contributed equally.

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal / adverse effects
Antibody-Dependent Cell Cytotoxicity
Antimetabolites, Antineoplastic / adverse effects
Azacitidine / adverse effects*
Drug Resistance, Neoplasm / drug effects*
Drug-Related Side Effects and Adverse Reactions / diagnosis*
Drug-Related Side Effects and Adverse Reactions / etiology
Female
Follow-Up Studies
Humans
Interleukin-3 Receptor alpha Subunit / antagonists & inhibitors*
Interleukin-3 Receptor alpha Subunit / immunology
Male
Myelodysplastic Syndromes / drug therapy*
Myelodysplastic Syndromes / immunology
Myelodysplastic Syndromes / pathology
Prognosis
Survival Rate

Substances

Antibodies, Monoclonal
Antimetabolites, Antineoplastic
IL3RA protein, human
Interleukin-3 Receptor alpha Subunit
Azacitidine